The Hemophilia B (Factor IX Deficiency) drugs in development market research report provides comprehensive information on the therapeutics under development for Hemophilia B (Factor IX Deficiency), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Hemophilia B (Factor IX Deficiency). Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Hemophilia B (Factor IX Deficiency) and features dormant and discontinued products.

GlobalData tracks 54 drugs in development for Hemophilia B (Factor IX Deficiency) by 50 companies/universities/institutes. The top development phase for Hemophilia B (Factor IX Deficiency) is preclinical with 29 drugs in that stage. The Hemophilia B (Factor IX Deficiency) pipeline has 45 drugs in development by companies and nine by universities/ institutes. Some of the companies in the Hemophilia B (Factor IX Deficiency) pipeline products market are: Pfizer, Sanofi and Novo Nordisk.

The key targets in the Hemophilia B (Factor IX Deficiency) pipeline products market include Coagulation Factor IX (Christmas Factor or Plasma Thromboplastin Component or F9 or EC 3.4.21.22), Coagulation Factor VII (Proconvertin or Serum Prothrombin Conversion Accelerator or SPCA or Eptacog Alfa or F7 or EC 3.4.21.21), and Tissue Factor Pathway Inhibitor (Extrinsic Pathway Inhibitor or EPI or Lipoprotein Associated Coagulation Inhibitor or LACI or TFPI).

The key mechanisms of action in the Hemophilia B (Factor IX Deficiency) pipeline product include Coagulation Factor IX (Christmas Factor or Plasma Thromboplastin Component or F9 or EC 3.4.21.22) Activator with 28 drugs in Pre-Registration. The Hemophilia B (Factor IX Deficiency) pipeline products include five routes of administration with the top ROA being Intravenous and ten key molecule types in the Hemophilia B (Factor IX Deficiency) pipeline products market including Gene Therapy, and Monoclonal Antibody.

Hemophilia B (Factor IX Deficiency) overview

Hemophilia B is a hereditary bleeding disorder caused by a lack of blood clotting factor IX. Symptoms include bleeding into joints and associated pain and swelling, bruising, excessive bleeding following circumcision, gastrointestinal tract and urinary tract hemorrhage, and nosebleeds. Treatment includes replacing the defective clotting factor.

For a complete picture of Hemophilia B (Factor IX Deficiency)’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.